1. Home
  2. DXLG vs CELU Comparison

DXLG vs CELU Comparison

Compare DXLG & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Destination XL Group Inc.

DXLG

Destination XL Group Inc.

N/A

Current Price

$0.51

Market Cap

38.2M

ML Signal

N/A

Logo Celularity Inc.

CELU

Celularity Inc.

N/A

Current Price

$1.19

Market Cap

34.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DXLG
CELU
Founded
1976
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.2M
34.5M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
DXLG
CELU
Price
$0.51
$1.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$2.50
$6.00
AVG Volume (30 Days)
125.7K
30.0K
Earning Date
04-14-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$467,015,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.24
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$1.01
52 Week High
$2.09
$4.35

Technical Indicators

Market Signals
Indicator
DXLG
CELU
Relative Strength Index (RSI) 33.73 42.08
Support Level N/A $1.01
Resistance Level $0.73 $1.33
Average True Range (ATR) 0.06 0.10
MACD 0.00 -0.01
Stochastic Oscillator 14.95 3.12

Price Performance

Historical Comparison
DXLG
CELU

About DXLG Destination XL Group Inc.

Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: